Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)

Inclusion Criteria: * Functional single ventricle patient with heart failure who is scheduled for stage 2 (Glenn) or stage 3 (Fontan) surgery * EF(%) by echocardiography ≤ 55% * Able to obtain written informed consent of participation in the study by a parent of the patient Exclusion Criteria: * Known medical history of cardiogenic shock * Lethal, uncontrollable arrhythmia * Complication of coronary artery disease * Eisenmenger syndrome * Complication of brain dysfunction due to circulatory failure * Malignant neoplasm * Complication of severe neurologic disorder * Severe pulmonary embolism or pulmonary hypertension * Severe renal failure * Multiple organ failure * Active infection (including endocarditis) * Sepsis * Active hemorrhagic disease (e.g. gastrointestinal bleeding, injury) * Known history of hypersensitivity to anti-infective drugs * Inability to complete the protocol treatment and baseline to follow-up examinations